T1	Participants 110 147	adults with major depressive disorder
T2	Participants 348 393	patients with major depressive disorder (MDD)
T3	Participants 161 277	This 8-week, randomized, double-blind, placebo-controlled study, conducted August 2010-May 2012 in the United States
T4	Participants 571 710	Adults aged 18-75 years with MDD (DSM-IV-TR) and Montgomery-Asberg Depression Rating Scale (MADRS) total score â‰¥ 26 were randomized (1:1:1)
T5	Participants 1147 1282	Of the 1,111 subjects screened, 469 subjects were randomized: 160 to placebo, 157 to vortioxetine 10 mg, and 152 to vortioxetine 15 mg.
T6	Participants 2086 2098	MDD subjects
